Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalidixic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.97 |
| ▸ | PKM | P14618 | 1/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 5/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalidixic Acid SCHEMBL21736 | 0.99 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL29367723 | 0.99 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL7878858 | 0.99 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL4766415 | 0.97 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL9743582 | 0.97 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL27256972 | 0.97 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL11472599 | 0.94 | KMT2A (0.90) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL11479648 | 0.94 | KMT2A (0.90) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL28206277 | 0.94 | KMT2A (0.90) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL2322952 | 0.92 | KMT2A (0.88) | KMT2AMEN1LMNAABCC4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173456-A1 | THERAPEUTIC COMPOSITIONS FOR WOUND TREATMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| EP-4359417-A2 | SMALL MOLECULE COMPOUNDS | Apertor Pharmaceuticals, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3607084-B1 | A METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | UNIV WESTERN AUSTRALIA (AU) | 2024-05-01 | — | — | EP | disclosed |
| EP-4358956-A1 | SMALL MOLECULE COMPOUNDS | Apertor Pharmaceuticals, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240077480-A1 | LATERAL FLOW ASSAY FOR DETECTING PATHOGENS IN MILK FROM MASTITIC COWS | ZOETIS SERVICES LLC | 2024-03-07 | — | — | US | disclosed |
| WO-2024018083-A1 | A VACCINE FOR TREATMENT OR PREVENTION OF VEROTOXIN-PRODUCING ESCHERICHIA COLI (VTEC) INFECTION | UNIVERSITY COLLEGE DUBLIN (IE) | 2024-01-25 | — | — | WO | disclosed |
| EP-4302090-A1 | LATERAL FLOW ASSAY FOR DETECTING PATHOGENS IN MILK FROM MASTITIC COWS | Zoetis Services LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117255946-A | Lateral flow assay for detecting pathogens in milk of mastitis cows | 硕腾服务有限责任公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2023201345-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230263778-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | GREGG JOHN M H (US) | 2023-08-24 | — | — | US | disclosed |
| CN-101909758-A | Sample preparation container and method | 3M INNOVATIVE PROPERTIES CO | 2010-12-08 | — | — | CN | disclosed |
| US-20100304998-A1 | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010049454-A2 | ANTIMICROBIAL COMPOSITION FROM COPEPODS | NOFIMA INGREDIENS (NO) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010009735-A2 | COMBINATORIAL ANALYSIS AND REPAIR | DAKO DENMARK A/S (DK) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009109194-A2 | DEVICE FOR PROMOTION OF HEMOSTASIS AND/OR WOUND HEALING | FERROSAN A/S (DK) | 2009-09-11 | — | — | WO | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |
| US-20070203079-A1 | Methods of using small molecule compounds for neuroprotection | ALABAMA, UNIVERSITY OF | 2007-08-30 | — | — | US | disclosed |
| CN-1802090-A | Boroproline compound combination therapy | POINT THERAPEUTICS INC (US) | 2006-07-12 | — | — | CN | disclosed |
| US-5147871-A | Anti-bacterial cephalosporin compounds | HOFFMANN LA-ROCHE, INC. (US) | 1992-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263778-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | ACE2, ACE, SARS1 | KMT2A 4816/4885MEN1 4836/4885LMNA 1742/4885 |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | CYFIP2, RPS27A, FRS2 | KMT2A 4275/4885MEN1 3261/4885LMNA 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.